Therapeutic role of rifampicin in Alzheimer's disease

• Published in: Psychiatry and clinical neurosciences Vol. 72; no. 3; pp. 152 - 159
• Main Authors: Yulug, Burak, Hanoglu, Lütfü, Ozansoy, Mehmet, Isık, Dogan, Kilic, Ulkan, Kilic, Ertugrul, Schabitz, Wolf Rüdiger
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.03.2018; Wiley Subscription Services, Inc
• Subjects: Alzheimer Disease - drug therapy; Alzheimer's disease; amyloid beta clearance; Cognitive ability; Humans; Inflammation; Neurodegenerative diseases; Neuroimaging; Neuroprotection; Neuroprotective Agents - pharmacology; Nootropic Agents - pharmacology; oligomeric amyloid hypothesis; rifampicin; Rifampin; Rifampin - pharmacology; Tau protein; rifampicin; amyloid beta clearance; oligomeric amyloid hypothesis; Alzheimer's disease; neuroprotection
• ISSN: 1323-1316; 1440-1819; 1440-1819
• DOI: 10.1111/pcn.12637

Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro‐cognitive effects of rifampicin that are mediated by its anti‐inflammatory, anti‐tau, anti‐amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro‐cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research.